Evidence, politics, and medical care technology -- Evolving public- and private-payer approaches to evidence and health technology assessment -- Mammography screening: vested interests and polarization -- When medicare said no for amyloid pet imaging -- Placing a value on cure: lessons from the new generation of hepatitis C drugs -- Avastin and the politics of accelerated approval -- The path to the clinic for stem cell and other regenerative medicine interventions -- Conclusion: the 21st century cures act and the future of health technology assessment
Summary
This book analyzes policy fights about what counts as good evidence of safety and effectiveness for new health care technologies in the U.S. and how political decisions affect patients and doctors. It discusses stakeholders' differing values and interests regarding patient choice, physician autonomy, risk assessment, government intervention in medicine and technology assessment, and scientific innovation as a driver of national and global economies
Bibliography
Includes bibliographical references and index
Notes
Print version record and CIP data provided by publisher; resource not viewed
